SG11201408800VA - Manufacture of 2- (5- bromo-4-(4-cyclopropylnaphthalen-1-yl) -4h-1,2,4-triazol-3-ylthio) acetic acid - Google Patents

Manufacture of 2- (5- bromo-4-(4-cyclopropylnaphthalen-1-yl) -4h-1,2,4-triazol-3-ylthio) acetic acid

Info

Publication number
SG11201408800VA
SG11201408800VA SG11201408800VA SG11201408800VA SG11201408800VA SG 11201408800V A SG11201408800V A SG 11201408800VA SG 11201408800V A SG11201408800V A SG 11201408800VA SG 11201408800V A SG11201408800V A SG 11201408800VA SG 11201408800V A SG11201408800V A SG 11201408800VA
Authority
SG
Singapore
Prior art keywords
international
llll
san diego
rule
hill
Prior art date
Application number
SG11201408800VA
Inventor
Esmir Gunic
Gabriel Galvin
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of SG11201408800VA publication Critical patent/SG11201408800VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 9 January 2014 (09.01.2014) WIPOIPCT (10) International Publication Number WO 2014/008295 A1 (51) International Patent Classification: C07D 249/12 (2006.01) A61P 9/00 (2006.01) A61K31/4196 (2006.01) A61P 29/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/049135 2 July 2013 (02.07.2013) English (30) Priority Data: 61/667,922 3 July 2012 (03.07.2012) English US (71) Applicant: ARDEA BIOSCIENCES, INC. [US/US]; 4939 Directors Place, San Diego, CA 92121 (US). (72) Inventors: GUNIC, Esmir; 8952 Capcano Rd., San Diego, CA 92129 (US). GALVIN, Gabriel; 13222 Salmon River Rd., San Diego, CA 92129 (US). (74) Agent: HARDT, Ingo, H.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) [Continued on next page] (54) Title: MANUFACTURE OF 2- (5- BROMO-4 (-CYCLOPROPYLNAPHTHALEN-1 -YL) -4H-l,2,4-TRIAZOL-3-YLTHIO) ACETIC ACID (57) Abstract: Described herein are certain processes for the synthesis of compounds of Formula (I): o\ CJ 00 o 20 30 40 2-Theta- Scale WO 2014/008295 A11II llll IIII III III Hill III III III Hill Hill llll llll lllll 111 mill llll 111 llll u ls e ' — before the expiration of the time limit for amending the — with international search report (Art. 21(3)) claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
SG11201408800VA 2012-07-03 2013-07-02 Manufacture of 2- (5- bromo-4-(4-cyclopropylnaphthalen-1-yl) -4h-1,2,4-triazol-3-ylthio) acetic acid SG11201408800VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261667922P 2012-07-03 2012-07-03
PCT/US2013/049135 WO2014008295A1 (en) 2012-07-03 2013-07-02 Manufacture of 2- (5- bromo-4 (-cyclopropylnaphthalen-1-yl) -4h-1,2,4-triazol-3-ylthio) acetic acid

Publications (1)

Publication Number Publication Date
SG11201408800VA true SG11201408800VA (en) 2015-01-29

Family

ID=49882471

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408800VA SG11201408800VA (en) 2012-07-03 2013-07-02 Manufacture of 2- (5- bromo-4-(4-cyclopropylnaphthalen-1-yl) -4h-1,2,4-triazol-3-ylthio) acetic acid

Country Status (26)

Country Link
US (2) US9296709B2 (en)
EP (1) EP2870142B1 (en)
JP (1) JP6124226B2 (en)
KR (1) KR20150028992A (en)
CN (1) CN104736522B (en)
AR (1) AR091651A1 (en)
AU (1) AU2013286739B2 (en)
BR (1) BR112015000160A2 (en)
CA (1) CA2878027A1 (en)
CO (1) CO7170165A2 (en)
ES (1) ES2609595T3 (en)
HK (1) HK1206359A1 (en)
HU (1) HUE031416T2 (en)
IL (1) IL236413A (en)
MX (1) MX352812B (en)
MY (1) MY174629A (en)
NZ (1) NZ631044A (en)
PL (1) PL2870142T3 (en)
PT (1) PT2870142T (en)
RU (1) RU2666549C2 (en)
SA (2) SA115360678B1 (en)
SG (1) SG11201408800VA (en)
SI (1) SI2870142T1 (en)
TW (2) TWI634110B (en)
WO (1) WO2014008295A1 (en)
ZA (1) ZA201409489B (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091651A1 (en) 2012-07-03 2015-02-18 Ardea Biosciences Inc ACID ELABORATION 2- (5-BROMO-4- (4-CICLOPROPILNAFTALEN-1-IL) -4H-1,2,4-TRIAZOL-3-ILTIO) ACETIC
WO2014198241A1 (en) * 2013-06-14 2014-12-18 Sunshine Lake Pharma Co., Ltd. Thio-1,2,4-triazole derivatives and method for preparing the same
CN103524440B (en) * 2013-10-15 2015-09-09 苏州鹏旭医药科技有限公司 The preparation method of gout therapertics Lesinurad and Lesinurad intermediate
CA2931430A1 (en) * 2013-11-22 2015-05-28 Crystal Pharmatech Co., Ltd. Crystalline forms of lesinurad and its sodium salt
EP3151817B1 (en) * 2014-06-06 2021-03-03 The Scripps Research Institute Sulfur(vi) fluoride compounds and methods for the preparation thereof
CN105294585B (en) * 2014-07-02 2019-02-12 成都海创药业有限公司 A kind of compound for treating gout
CN105315218A (en) * 2014-07-17 2016-02-10 天津药物研究院 Preparation method of lesinurad intermediate namely 1-naphthyltriazole thioketone
CN104311498B (en) * 2014-10-27 2016-04-06 张远强 Triazole sulphonyl propanedioic acid compounds, Preparation Method And The Use that alkoxyl group replaces
CN104341361B (en) * 2014-10-27 2017-01-11 张远强 Cyano-substituted triazolesulfonylmalonic acid compounds as well as preparation method and application thereof
CN104326999B (en) * 2014-10-27 2017-01-18 张远强 Alkoxy-substituted triazole sulfinyl malonate type compound, and preparation method and application thereof
CN105820130B (en) * 2015-01-08 2018-06-22 天津药物研究院有限公司 Triazole n Propanoic acid class URAT1 inhibitor, preparation method and its purposes in hyperuricemia and gout treatment
CN105985296B (en) * 2015-02-13 2018-10-16 天津药物研究院有限公司 It is a kind of can be with the process for refining of industrialized lesinurad intermediates 1- naphthalene triazolinthiones
CN109053608A (en) * 2015-02-17 2018-12-21 华润赛科药业有限责任公司 A kind of optically pure thioacetic acid class compound, its pharmaceutical composition and purposes
CN104788318A (en) * 2015-03-23 2015-07-22 爱斯特（成都）生物制药有限公司 Method for preparing 4-nitro-cyclopropyl-naphthalene
CN105622531A (en) * 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 Axial chiral isomers and preparation method and pharmaceutical application thereof
CN104817509B (en) * 2015-04-13 2019-05-17 安徽省逸欣铭医药科技有限公司 Lesinurad analog and preparation method thereof and medical usage
CN106187926B (en) 2015-04-30 2018-11-27 天津药物研究院有限公司 Carboxylic acids URAT1 inhibitor, preparation method and its purposes in hyperuricemia and gout treatment of the structure containing diarylmethanes
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
CN104987311A (en) * 2015-06-30 2015-10-21 安徽万邦医药科技有限公司 Preparing method for (4-(4-cyclopropyl-naphthalene-1-yl)-5-nitr-4H-(1, 2, 4) triazole-3-ylsulfanyl)-ethyl acetate and intermediate (5-nitr-4H-(1, 2, 4) triazole-3-sulfenyl)-ethyl acetate thereof
CN105017168A (en) * 2015-07-01 2015-11-04 安徽万邦医药科技有限公司 New preparation method of [5-bromo-4-(4-cyclopropyl-naphthalene-1-yl)-4H-[1, 2, 4]triazole-3-ylsulfanyl]-methyl acetate
WO2017036884A1 (en) 2015-08-28 2017-03-09 Sandoz Ag A lesinurad, free form / lesinurad ethyl ester co-crystal
CN105175348A (en) * 2015-10-16 2015-12-23 北京康立生医药技术开发有限公司 Preparation method for lesinurad
CN105399694B (en) * 2015-12-11 2017-09-15 浙江京新药业股份有限公司 Medicine Lesinurad axial chirality enantiomers
WO2017147270A1 (en) * 2016-02-24 2017-08-31 Ardea Biosciences, Inc. Atropisomers of triazole derivative
CN105906576B (en) * 2016-06-12 2018-04-17 成都百裕制药股份有限公司 It is a kind of come Si Nuolei intermediates preparation method
CN106083680B (en) * 2016-06-21 2018-11-02 山东川成医药股份有限公司 A kind of preparation method of 4- cyclopropyl -1- naphthalenylisothiocyanates
CN106187927B (en) * 2016-07-26 2020-02-04 山东川成医药股份有限公司 Preparation method of Lesinurad intermediate
CN106220577A (en) * 2016-07-26 2016-12-14 苏州明锐医药科技有限公司 The preparation method of Li Xinluode
EP3281941B1 (en) 2016-08-11 2019-07-24 Zentiva K.S. Process for preparing 2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid
CN106632108A (en) * 2016-12-14 2017-05-10 湖南欧亚生物有限公司 Preparation method of lesinurad
EP3372592A1 (en) 2017-03-07 2018-09-12 Zentiva, k.s. Solid forms of lesinurad amine salts
US10351537B2 (en) 2017-03-10 2019-07-16 Apotex Inc. Processes for the preparation of lesinurad and intermediates thereof
EP3315494A1 (en) 2017-04-19 2018-05-02 Química Sintética, S.A. Amorphous form of lesinurad and processes for its preparation
CN108947919B (en) 2017-05-17 2023-05-02 上海奥博生物医药股份有限公司 Novel preparation method of anti-gout drug Lesinurad and key intermediate thereof
CN109206323A (en) * 2017-07-07 2019-01-15 上海现代制药股份有限公司 A kind of preparation method of naphthylamines pharmaceutical intermediate
CN107739344A (en) * 2017-10-10 2018-02-27 浙江新东港药业股份有限公司 Prepare Lesinurd method and its intermediate
EP3498697A1 (en) 2017-12-12 2019-06-19 Química Sintética, S.A. Novel salts and polymorphs of lesinurad
CN109970667A (en) * 2017-12-27 2019-07-05 徐州万邦金桥制药有限公司 A kind of refining methd of the western Nader of thunder
CN108047148A (en) * 2017-12-28 2018-05-18 北京沃邦医药科技有限公司 A kind of preparation method of the western Nader's impurity of thunder
CN110878045A (en) * 2018-09-05 2020-03-13 江西同和药业股份有限公司 Compound and preparation method and application thereof
CN111116500B (en) * 2019-12-30 2021-06-08 北京鑫开元医药科技有限公司海南分公司 Purification method of Resinard key intermediate
CN111116501B (en) * 2019-12-30 2021-03-12 北京鑫开元医药科技有限公司海南分公司 Synthesis method of Ravinard intermediate capable of effectively reducing impurity content
CN112778223A (en) * 2021-01-25 2021-05-11 海南鑫开源医药科技有限公司 Preparation method of Raschindde oxidation impurities

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1697650B (en) 2002-08-23 2010-11-10 阿迪亚生命科学公司 Non-nucleoside reverse transcriptase inhibitors
SG155246A1 (en) 2004-08-25 2009-09-30 Ardea Biosciences Inc S-TRIAZOLYL α-MERCAPTOACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
TWI415840B (en) * 2007-11-27 2013-11-21 Ardea Biosciences Inc Novel compounds and compositions and methods of use
JP2012502050A (en) 2008-09-04 2012-01-26 アルディア バイオサイエンス，インク． Compounds, compositions and methods of using the same for regulating uric acid levels.
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
SG182404A1 (en) 2010-01-08 2012-08-30 Ardea Biosciences Inc Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof
WO2011126852A2 (en) 2010-03-30 2011-10-13 Ardea Biosciences, Inc. Treatment of gout
ES2670700T3 (en) 2010-06-15 2018-05-31 Ardea Biosciences, Inc. Gout and hyperuricemia treatment
EP2627331A4 (en) 2010-10-15 2014-03-12 Ardea Biosciences Inc Methods for treating hyperuricemia and related diseases
EA022301B1 (en) 2010-12-30 2015-12-30 Ардеа Биосайнсиз, Инк. Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
AR091651A1 (en) 2012-07-03 2015-02-18 Ardea Biosciences Inc ACID ELABORATION 2- (5-BROMO-4- (4-CICLOPROPILNAFTALEN-1-IL) -4H-1,2,4-TRIAZOL-3-ILTIO) ACETIC

Also Published As

Publication number Publication date
ZA201409489B (en) 2019-01-30
JP6124226B2 (en) 2017-05-10
US20150252010A1 (en) 2015-09-10
US20160214947A1 (en) 2016-07-28
TWI634110B (en) 2018-09-01
EP2870142A4 (en) 2016-01-06
SA115360678B1 (en) 2016-09-08
US9296709B2 (en) 2016-03-29
SA113340696B1 (en) 2016-03-06
MY174629A (en) 2020-05-03
IL236413A0 (en) 2015-02-26
TWI621615B (en) 2018-04-21
KR20150028992A (en) 2015-03-17
JP2015525749A (en) 2015-09-07
WO2014008295A1 (en) 2014-01-09
MX352812B (en) 2017-12-08
AU2013286739B2 (en) 2017-02-23
EP2870142B1 (en) 2016-10-19
AR091651A1 (en) 2015-02-18
CN104736522B (en) 2018-10-09
ES2609595T3 (en) 2017-04-21
HUE031416T2 (en) 2017-07-28
AU2013286739A1 (en) 2015-01-22
PT2870142T (en) 2016-12-27
WO2014008295A8 (en) 2015-01-08
SI2870142T1 (en) 2017-02-28
MX2015000082A (en) 2015-09-04
BR112015000160A2 (en) 2017-06-27
RU2015102723A (en) 2016-08-20
CN104736522A (en) 2015-06-24
CO7170165A2 (en) 2015-01-28
CA2878027A1 (en) 2014-01-09
TW201406734A (en) 2014-02-16
IL236413A (en) 2016-11-30
HK1206359A1 (en) 2016-01-08
RU2666549C2 (en) 2018-09-18
NZ631044A (en) 2015-12-24
EP2870142A1 (en) 2015-05-13
PL2870142T3 (en) 2017-04-28
TW201604186A (en) 2016-02-01

Similar Documents

Publication Publication Date Title
SG11201408800VA (en) Manufacture of 2- (5- bromo-4-(4-cyclopropylnaphthalen-1-yl) -4h-1,2,4-triazol-3-ylthio) acetic acid
SG11201909011PA (en) Niraparib compositions
SG11201408629QA (en) Dimethyl-benzoic acid compounds
SG11201805838UA (en) Macrocyclic mcl1 inhibitors for treating cancer
SG11201908947QA (en) Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201809554VA (en) Methods of treating skin cancer by administering a pd-1 inhibitor
SG11201407793TA (en) Compounds and compositions for modulating egfr activity
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201803627XA (en) N-substituted indole derivatives as pge2 receptor modulators
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201406973PA (en) Complement pathway modulators and uses thereof
SG11201408261UA (en) Syringe
SG11201407472SA (en) Motion compensation and motion estimation leveraging a continuous coordinate system
SG11201408140QA (en) Crystalline forms of an androgen receptor modulator
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201408069XA (en) Hair styling device
SG11201407115XA (en) Carboxylic acid compounds
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201407345QA (en) Pyrazole compounds as sglt1 inhibitors
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions
SG11201407184PA (en) Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds